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Purpose or Objective: To evaluate local control, 
enucleation-free survival, toxicity and cost-effectiveness in 
patients with choroidal melanoma treated with linac-based 
stereotactic radiosurgery (SRS). GammaKnife® radiosurgery 
has report very good results for this melanoma treatment.  
 
Material and Methods: Between 2003-2014, 6 patients with 
choroidal melanoma were treated at NISA Virgen del 
Consuelo Hospital in Valencia, Spain. Mean age was 59 years 
(range 43-79). Three were men and three women. Metastatic 
disease was ruled out in all cases. Two patients had small 
tumors, two medium sized lesions and two had large lesions 
according to Collaborative Ocular Melanoma Study 
Classification. Mean tumor volume was 0,49 cm3 (range 0,17-
0,93). Three tumors were localized in the right eye. Visual 
field previous to treatment was normal in 5 cases and one 
patient presented complete hemianopsia of the affected eye. 
Central vision was preserved in all cases. The procedure was 
made under sedation and retrobulbar blockage, the eye 
muscles were fixed to Leksell G-Frame with silk sutures. 
Magnetic resonance (MRI) and computed tomography (CT) 
were used to contour lesion. CTV minimal marginal dose is 30 
Gy, encompassed the 80 % isodose line in 4 patients and the 
60% and 55% isodose lines in the other cases. All were treated 
with 6 MV linac, one isocenter and cone-colimation. Global 
cost of this method is around 8.000 € (range 7.000-12.000). It 
is an ambulatory procedure with a total duration of 3 hours 
or less. 
 
Results: Median follow-up is 19 months (range 1-69). Follow 
up includes MRI and ophthalmoscopy every 6 months. 
Complete response in one patient, maximal partial response 
(≥ 50%) in three patients, partial response (≤ 50%) in other 
patient and it’s too early for response evaluation (less than 6 
weeks) in the last one. For lens and optic nerve, the dose 
constraints were 4 and 18 Gy, respectively. Up to date, no 
patient has local or distance progression. Enucleation has not 
been necessary in any patients. Five years after treatment 
one patient presented retinal scarring in irradiated area. 
Glaucoma start 9 month after SRS in one patient with 
previous cataract surgery. No other toxicities were observed.  
 
Conclusion: In our experience, linac SRS is effective eye and 
vision-sparing method to treat patients with a minimally 
invasive, safe and cost-efficient alternative to brachytherapy 
and enucleation in choroidal melanoma with high local 
control rates and low incidence of toxicities.  
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Purpose or Objective: The immunotherapy improves survival 
in patients (pts) with metastatic melanoma, but there is 
insufficient data on the efficacy in pts with brain metastases. 
SRS and SRT allow greater local control in pts with melanoma 
brain metastases, with not significant impact on prognosis. 
Our analysis evaluated survival and local control in pts 
treated with SRT/SRS with Cyberknife® system and 
Immunotherapy.  
 
Material and Methods: From November 2012 to September 
2015 we treated 47 pts (26 M and 21 F) with melanoma brain 
metastases. The median age was 59 years (28-81y). 28 pts 
received immunotherapy pre (pre-RT), concomitant and post 
radiation treatment (post-RT). 26 pts received Ipilimumab: 
14 pts pre-RT, 5 pts concomitant-RT, 7 pts post-RT; 2 pts 
received Nivolumab: 1 pt pre-RT and 1 pt concomitant-RT; 11 
pts received Pembrolizumab: 3 pts pre-RT, 4 pts concomitant 
RT, 4 pts post-RT. we treated 91 lesions of average size 13.5 
mm (2-36). Based on the number of lesions, size and 
location, 69 lesions were treated with SRS (10-24Gy), 22 with 
SRT (18-24Gy/2-3-5 fractions). We evaluated the local 
response according to RECIST criteria (complete response CR: 
disappearance of the lesion; partial response PR: at least a 
30% decrease in the diameter of lesion; progression disease 
PD: increase in the diameter of the lesion > 20%; stable 
disease SD: everyone else). We assessed overall survival, 
local control (LC) as the sum of CR, PR and SD, and the 
impact on LC of the association Radiotherapy (RT) and 
immunotherapy. 
 
Results: 41 pts were evaluable for follow-up (FU). The 6-
month survival was 58%. 11 patients died and 11 pts received 
Whole Brain RT for progression disease. At two months FU, of 
the 39 pts evaluable (24 treated with RT and 
immunotherapy), 85% had LC; at four months FU, of 29 pts 
evaluable (20 treated with RT and immunotherapy), 81% had 
LC; at six months FU, the 24 pts evaluable (15 treated with 
RT and Immunotherapy) 100% had LC. 
 
Conclusion: Our analysis seems to confirm the literature data 
in terms of overall survival. The results showed a good 
disease local control in pts treated with SRT/SRS and 
immunotherapy, demonstrating a potential role of 
immunotherapy in the treatment of melanoma brain 
metastases. the recruitment of a greater number of pts, a 
longer follow-up and new prospective studies of combination 
RT and immunotherapy are needed to demonstrate the 
immunotherapy role in the treatment of melanoma brain 
metastases. 
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Purpose or Objective: Adjuvant radiotherapy is proven to 
prevent lymph-node field relapse after therapeutic 
lymphadenectomy for melanoma, but does not improve 
overall survival. Risk factors for lymph-node field recurrence 
include presence of extracapsular extension, number and size 
of lymph nodes at dissection. This study reports patterns of 
failure in patients treated with adjuvant radiotherapy post 
lymphadenectomy for melanoma. 
 
Material and Methods: This retrospective study included all 
patients in three institutions treated with adjuvant 
radiotherapy post lymphadenectomy for melanoma between 
June 2012 and March 2015. 
Patients who received radiotherapy were those with high risk 
of lymph node field recurrence, as per the findings of 
Burmeister et al in 2012. Patients received radiotherapy to 
the head & neck (55%), groin (30%) and axilla (15%). All were 
staged with PET or CT. Both IMRT (50%) and 3D conformal 
(50%) techniques were used. 
 
Results: 20 patients were treated during this period (see 
table). Median follow up was 16 months (range 6.7 - 32 
months).  
There were no lymph node field recurrences. 
Local recurrence rate was 10%. 
Distant recurrence rate was 35%, all occurring within 4 
months from completion of radiotherapy.  
Distant recurrence rate was 53.8% in patients with 
extracapsular extension. 
All patients with local or distant relapse had extracapsular 
extension. 
71% of patients with distant recurrence had PET staging. 
8% of patients experienced grade 3 radiotherapy toxicity. 
 
 
